Men | Women | |||||||
---|---|---|---|---|---|---|---|---|
MetSc | MetSc | |||||||
Yes | No | OR (95% CI)a | OR (95% CI)b | Yes | No | OR (95% CI)a | OR (95% CI)b | |
Relative MVPAd recommendation | ||||||||
Below | 86 | 80 | 1.74 (1.19–2.53) | 1.59 (1.08–2.33) | 49 | 52 | 2.15 (1.39–3.33) | 2.12 (1.36–3.31) |
Meeting | 132 | 211 | 1.00 (Reference) | 1.00 (Reference) | 142 | 324 | 1.00 (Reference) | 1.00 (Reference) |
Relative MPA recommendation | ||||||||
Below | 215 | 287 | 1.00 (0.22–4.54) | 0.87 (0.18–4.09) | 182 | 355 | 1.19 (0.53–2.66) | 1.11 (0.49–2.51) |
Meeting | 3 | 4 | 1.00 (Reference) | 1.00 (Reference) | 9 | 21 | 1.00 (Reference) | 1.00 (Reference) |
Relative VPAe recommendation | ||||||||
Below | 91 | 76 | 2.02 (1.39–2.95) | 1.81 (1.23–2.67) | 57 | 67 | 1.96 (1.30–2.95) | 1.95 (1.29–2.95) |
Meeting | 127 | 215 | 1.00 (Reference) | 1.00 (Reference) | 134 | 309 | 1.00 (Reference) | 1.00 (Reference) |